No Data
Harrow Is Maintained at Buy by Craig-Hallum
Harrow Is Maintained at Buy by Craig-Hallum
Harrow Price Target Raised to $26.00/Share From $24.00 by Craig-Hallum
Harrow Price Target Raised to $26.00/Share From $24.00 by Craig-Hallum
Express News | B. Riley Securities Reiterates Buy on Harrow, Raises Price Target to $29
Harrow Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 75.76% B. Riley Securities $26 → $29 Reiterates Buy → Buy 04/11/2024 45.45% Craig-Hallum → $24
Express News | Harrow, Inc. : Craig-Hallum Raises Target Price to $26 From $24
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor